- Conditions
- Prostate Neoplasms
- Interventions
- Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide, Theophylline
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hepatitis C, Chronic
- Interventions
- midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
- Conditions
- AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
- Interventions
- Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Advanced Solid Tumors, Excluding Breast Cancer
- Interventions
- caffeine, diclofenac, omeprazole, midazolam, TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
- Conditions
- Sickle Cell Disease
- Interventions
- GBT440
- Drug
- Lead sponsor
- Global Blood Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Drug Interactions
- Interventions
- Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Food-drug Interaction
- Interventions
- Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg
- Dietary Supplement · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 40 Years to 79 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois